Keytruda (Pembrolizumab) Insurance Denial Appeal Guide

Keytruda (pembrolizumab) is a PD-1 checkpoint inhibitor immunotherapy approved for over 30 cancer indications. Despite being standard of care for many cancers, prior authorization denials and indication restrictions can delay critical treatment.

FDA-Approved Indications (Selected)

  • Non-small cell lung cancer (NSCLC) — first-line and subsequent
  • Melanoma — adjuvant and unresectable/metastatic
  • Head and neck squamous cell carcinoma
  • Classical Hodgkin lymphoma
  • Urothelial carcinoma
  • Microsatellite instability-high (MSI-H) cancers
  • Gastric/GEJ cancer
  • Cervical cancer
  • Hepatocellular carcinoma
  • Merkel cell carcinoma
  • Renal cell carcinoma
  • Endometrial cancer
  • Triple-negative breast cancer
  • And many more

Common Denial Reasons

  1. Biomarker testing not completed (PD-L1, MSI, TMB)
  2. Indication not FDA-approved (off-label use)
  3. Prior authorization documentation insufficient
  4. Alternative first-line treatment required
  5. Non-formulary for the specific cancer type

Appeal Strategy

  1. Biomarker documentation — ensure PD-L1 TPS, MSI, or TMB results are included
  2. NCCN guidelines — cite the National Comprehensive Cancer Network guidelines (Category 1 evidence)
  3. FDA compendia — reference FDA-approved indication or NCCN-recommended off-label use
  4. Oncologist urgency letter — cancer treatment is time-sensitive
  5. Request expedited appeal — cite the urgent nature of cancer treatment
  6. Right to try — for advanced cancer with limited options

Off-Label Cancer Use

NCCN Category 2A recommendations for off-label use are generally sufficient for insurance coverage under most state prompt and federal compendia laws.

Detailed Guides

Appealing Off-Label Keytruda Coverage Denials

How to appeal off-label Keytruda (pembrolizumab) insurance denials. NCCN compendia support, clinical trial data, and coverage arguments.

Need Help Writing Your Appeal?

Our AI-powered tool analyzes your denial letter and generates a personalized appeal in minutes. Upload your denial and get started for free.

Start Your Free Appeal

Frequently Asked Questions

How much does Keytruda cost?

Keytruda costs approximately $10,000-$12,000 per infusion (every 3-6 weeks depending on the regimen). Annual costs can exceed $150,000. This makes insurance coverage essential, and appeals should be filed promptly if denied.

Can insurance deny Keytruda for cancer?

Yes, insurers can deny Keytruda for various reasons including incomplete biomarker testing, insufficient documentation, or the specific cancer indication not matching your plan's criteria. However, denials for FDA-approved or NCCN-recommended uses are generally overturned on appeal.

Related Resources